Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 12/20 | 0.58 |
| ▸ | EGFR | P00533 | 10/20 | 0.58 |
| ▸ | ABL1 | P00519 | 9/20 | 0.58 |
| ▸ | ABL2 | P42684 | 9/20 | 0.58 |
| ▸ | LCK | P06239 | 4/20 | 0.50 |
| ▸ | RET | P07949 | 3/20 | 0.50 |
| ▸ | KDR | P35968 | 3/20 | 0.50 |
| ▸ | LYN | P07948 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.50 |
| ▸ | INSR | P06213 | 1/20 | 0.50 |
| ▸ | NPM1 | P06748 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
| ▸ | MET | P08581 | 1/20 | 0.50 |
| ▸ | ROS1 | P08922 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | KIT | P10721 | 1/20 | 0.50 |
| ▸ | BCR | P11274 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30813394 | 1.00 | SRC (0.58) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL27217772 | 0.96 | SRC (0.57) | SRCEGFRABL1ABL2RET | |
| SCHEMBL30813385 | 0.96 | SRC (0.57) | SRCEGFRABL1ABL2RET | |
| SCHEMBL30813428 | 0.81 | SRC (0.55) | SRCEGFRABL1ABL2RET | |
| SCHEMBL27217872 | 0.81 | SRC (0.55) | SRCEGFRABL1ABL2RET | |
| SCHEMBL27217870 | 0.79 | IGF1R (0.47) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL30813404 | 0.79 | IGF1R (0.47) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL30813574 | 0.79 | SRC (0.40) | SRCEGFRABL1ABL2RIPK2 | |
| SCHEMBL30813461 | 0.78 | RIPK2 (0.56) | SRCEGFRABL1ABL2RET | |
| SCHEMBL27217819 | 0.78 | RIPK2 (0.56) | SRCEGFRABL1ABL2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| WO-2024059200-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | SRC 1597/4885EGFR 4857/4885ABL1 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.